Get started
Tonix Pharmaceuticals Holding Corp.Tonix Pharmaceuticals Holding Corp.Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

TNXP trade ideas

TNXP high potential and hopes. With TNXP developing a new covid vaccine named TNX-1800, I think it looks bullish af. They are now in between phase 1 and 2 with the vaccine and it is expected that they will announce the results in July. With janssen&janssen or astrazeneca vaccines doing bad I think TXNP has a lot of potential. We know what happend to OCGN when they announced their vaccine, so Im hoping to see the same here with TNXP. Chart also looks good and if everything goes well my TP1 is 2 dollars and if we break that 4 and 6 dollars will follow. Cheers!
NASDAQ:TNXPLong
by malo-melo
TXNP - Cup & Handle Pattern FormationTNXP Daily Chart Analysis: (1) Cup-Handle pattern formation on the daily chart (2) On February 09, 2021 company announced the closing of its previously announced registered direct offering, priced at-the-market, with gross proceeds of approximately $70.0 million. (3) On March 04, 2021 company announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market. (4) On March 15, 2021 company announced that 50 percent of the planned total number of participants have been randomized in the Phase 3 RALLY study (TNX-CY-F306) for the management of fibromyalgia. (5) On March 17, 2021 company announced preliminary results following vaccination of non-human primates with TNX-1800 (modified horsepox virus, live vaccine), a live attenuated COVID-19 vaccine candidate engineered to express the SARS-CoV-2 (CoV-2) spike protein. A bullish flag formed on the 5min chart on 03/17 so we can expect continued upward momentum into the week's close. Price Target of $6.00 by end of Q2. Disclaimer: This written/visual material is comprised of personal opinions and ideas.
NASDAQ:TNXPLong
by Mathematikoi_BC
4
$TNXPTonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, manufacturing, and licensing small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 and TNX-2600, which are live replicating attenuated vaccine candidates for the prevention of COVID-19. In addition, the company's lead CNS candidate is TNX-102 SL, a sublingual formulation of cyclobenzaprine, which is in Phase 3 development for fibromyalgia, as well as in Phase 2 studies for agitation in Alzheimer's disease and alcohol use disorder. Further, its products include TNX-1300, which is in Phase 2 development for the treatment of life-threatening cocaine intoxication; TNX-601 CR for depression; and TNX-1900 for migraine and cranio-facial pain treatment. Additionally, its preclinical pipeline includes TNX-1600 for posttraumatic stress disorder, depression, and attention deficit hyperactivity disorder; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500 for transplant organ rejection and autoimmune conditions; and TNX-1700 for gastric and pancreatic cancers. The company is headquartered in Chatham, New Jersey.
NASDAQ:TNXPLong
by BADQOMOCAWGOWLD
1